NEWS! NEWS! NEWS! Halberd's 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater
Press Release | 03/02/2021
JACKSON CENTER, PA / ACCESSWIRE / March 2, 2021 /
Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV-2 Spike protein.
Dr. Reyes, Halberd's Chief Technical Officer, indicated, "Our latest results indicate increased specificity of our second antibody, which can be used as a stand-alone or in combination with other antibodies for the overall optimum management of COVID-19. Based on our commitment to develop the best diagnostic and therapeutic approach to COVID-19, we will continue to generate antibodies with unique properties, and design in-vivo experiments to prove our products' sensitivity and specificity."
William A. Hartman, Chairman, President & CEO, stated, "We are excited about the progress being made in developing Halberd's effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best known competitive SARS-COV-2 antibodies. Our researchers continue work to develop additional antibodies targeting not only the characteristic S-protein, but also the lesser known nucleocapsid (N-antigen) protein. By combining these two classes of S- and N-protein antibodies, we hope to deliver a superior "1-2 punch" to eliminate SARS-COV-2, and variants.
"Recognizing the value of partnership and collaboration, we hope our recent results would be of great interest to bio-tech and pharmaceutical companies as well as medical and scientific institutions currently involved in the fight against the current pandemic. We intend to contact select organizations to initiate discussions illustrating the advantages of partnering with Halberd to optimize Covid treatment effectiveness.
"Independent of any potential partnership, we intend to utilize our demonstrably stronger SARS-COV-2 antibody in our patented extracorporeal radio frequency project, which has already been launched with Dr Chen and staff at GreenBioAZ. This Halberd RF project has four distinct phases, any one of which will represent a major accomplishment in the conquering of select classes of diseases. Major attention by potential partners is expected as each phase of the project is completed. This technology could revolutionize medicine in that it is designed to eliminate all diseases, whether blood-born or neurological, without side effects. More information on each phase of the experiment will be forthcoming shortly."
"We are also in the process of completing the development, manufacture, and distribution plans for our immune booster vitamins. We will announce the product name, availability and further progress, via separate press releases and tweets.